These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20438803)

  • 1. Pituitary tumours: the sst/D2 receptors as molecular targets.
    Hofland LJ; Feelders RA; de Herder WW; Lamberts SW
    Mol Cell Endocrinol; 2010 Sep; 326(1-2):89-98. PubMed ID: 20438803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin and somatostatin receptors in Cushing's disease.
    Hofland LJ
    Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of somatostatin receptors in normal and tumoral pituitary corticotropic cells.
    Hofland LJ; Lamberts SW; Feelders RA
    Neuroendocrinology; 2010; 92 Suppl 1():11-6. PubMed ID: 20829612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro.
    de Bruin C; Feelders RA; Waaijers AM; van Koetsveld PM; Sprij-Mooij DM; Lamberts SW; Hofland LJ
    J Mol Endocrinol; 2009 Jan; 42(1):47-56. PubMed ID: 18852217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of somatostatin and dopamine D2 receptors in endocrine tumors.
    Gatto F; Hofland LJ
    Endocr Relat Cancer; 2011 Dec; 18(6):R233-51. PubMed ID: 22135243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
    Saveanu A; Jaquet P; Brue T; Barlier A
    Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.
    Saveanu A; Lavaque E; Gunz G; Barlier A; Kim S; Taylor JE; Culler MD; Enjalbert A; Jaquet P
    J Clin Endocrinol Metab; 2002 Dec; 87(12):5545-52. PubMed ID: 12466351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules.
    Gruszka A; Ren SG; Dong J; Culler MD; Melmed S
    Endocrinology; 2007 Dec; 148(12):6107-14. PubMed ID: 17656461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.
    Gatto F; Barbieri F; Gatti M; Wurth R; Schulz S; Ravetti JL; Zona G; Culler MD; Saveanu A; Giusti M; Minuto F; Hofland LJ; Ferone D; Florio T
    Clin Endocrinol (Oxf); 2012 Mar; 76(3):407-14. PubMed ID: 21848909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
    Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD
    J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
    van der Pas R; Feelders RA; Gatto F; de Bruin C; Pereira AM; van Koetsveld PM; Sprij-Mooij DM; Waaijers AM; Dogan F; Schulz S; Kros JM; Lamberts SW; Hofland LJ
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1880-90. PubMed ID: 24081741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
    Ishibashi M; Yamaji T
    J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors.
    Hofland LJ; De Herder WW; Visser-Wisselaar HA; Van Uffelen C; Waaijers M; Zuyderwijk J; Uitterlinden P; Kros MJ; Van Koetsveld PM; Lamberts SW
    J Clin Endocrinol Metab; 1997 Sep; 82(9):3011-8. PubMed ID: 9284735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New medical treatments in pituitary adenomas].
    Drutel A; Caron P; Archambeaud F
    Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S16-28. PubMed ID: 18954854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
    Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
    J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New SRIF analogs in the control of human pituitary adenomas: perspectives.
    Jaquet P; Saveanu A; Barlier A
    J Endocrinol Invest; 2005; 28(5 Suppl):14-8. PubMed ID: 16114269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The somatostatin receptor subtype 5 in neuroendocrine tumours.
    van der Hoek J; Lamberts SW; Hofland LJ
    Expert Opin Investig Drugs; 2010 Mar; 19(3):385-99. PubMed ID: 20151855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of somatostatin receptors, dopamine D₂ receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas.
    Saveanu A; Muresan M; De Micco C; Taieb D; Germanetti AL; Sebag F; Henry JF; Brunaud L; Enjalbert A; Weryha G; Barlier A
    Endocr Relat Cancer; 2011 Apr; 18(2):287-300. PubMed ID: 21335363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology.
    Ferone D; Gatto F; Arvigo M; Resmini E; Boschetti M; Teti C; Esposito D; Minuto F
    J Mol Endocrinol; 2009 May; 42(5):361-70. PubMed ID: 19141603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas.
    Cuevas-Ramos D; Fleseriu M
    J Mol Endocrinol; 2014 Jun; 52(3):R223-40. PubMed ID: 24647046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.